SS-31 Peptide, MOTS-c and NAD+: What Mitochondrial Peptide Research Shows

The SS-31 peptide and the MOTS-c peptide are usually filed together under "mitochondrial peptides", often with NAD+ alongside them. The grouping is convenient but hides a large difference in evidence. One of these compounds has a regulatory history and registered clinical trials, one is a naturally occurring peptide studied mostly in mice, and one is not a peptide at all. This review sets out what each is, what the published studies actually report, and where that evidence stops.
Why "mitochondrial peptides" is a loose label
Mitochondria convert nutrients into usable chemical energy through the electron transport chain on their folded inner membrane. Compounds get the "mitochondrial" label for quite different reasons: SS-31 because it is designed to bind a lipid found in that inner membrane, MOTS-c because it is encoded by mitochondrial DNA, and NAD+ because it is a coenzyme that carries electrons in energy metabolism. Same organelle, three unrelated questions. Keeping them apart is the first step in reading the literature honestly.
SS-31 (elamipretide): structure and mechanism
SS-31, also known as elamipretide and MTP-131, is a synthetic Szeto-Schiller tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine and the D-arginine and C-terminal amide are deliberate design choices. It is aimed at the inner mitochondrial membrane.
The proposed mechanism centres on cardiolipin, a phospholipid concentrated in that membrane. In laboratory studies SS-31 binds cardiolipin through electrostatic and hydrophobic interactions. That binding limits cardiolipin's ability to turn cytochrome c into a peroxidase while preserving cytochrome c's normal role in carrying electrons, and it is associated with preserved cristae structure and oxidative phosphorylation (Szeto, 2014).
Elamipretide research: where the human data sit
Elamipretide research is unusual among catalogue peptides because it reached registered clinical trials. Studied areas include Barth syndrome, primary mitochondrial myopathy, heart failure with reduced ejection fraction and age-related macular degeneration; these are listed here as areas investigated, not as outcomes. In Barth syndrome, a 168-week open-label extension of the TAZPOWER study followed a small group of patients, ten at entry and eight at week 168, with sponsor-affiliated authors (Thompson et al., 2024).
As elamipretide hydrochloride, under the brand name FORZINITY, the compound received FDA accelerated approval on 19 September 2025 for a single rare-disease indication in Barth syndrome (U.S. FDA, 2025). The approval was based on an intermediate endpoint, and continued approval depends on confirmatory trials; the label describes the drug as a mitochondrial cardiolipin binder (Stealth BioTherapeutics, 2025).
Where the evidence stops: the approval covers one specific, manufactured drug product for one indication. Every other use remains investigational, the long-term extension data come from a very small open-label cohort, and none of it describes research-grade material. Our SS-31 research vials are sold for laboratory work only and carry no approval of any kind.
MOTS-c peptide: a mitochondria-encoded signal
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame inside the 12S rRNA region of mitochondrial DNA. It was first described in 2015, which makes it a young literature, and it belongs to a small family of "mitochondrial-derived peptides" that also includes humanin.
In the original cell and mouse studies, MOTS-c acted primarily on skeletal muscle. There it inhibited the folate cycle and the linked de novo purine synthesis, which led to activation of AMPK, a cellular energy sensor. The same paper reported metabolic effects in mouse models of diet-induced obesity and insulin resistance (Lee et al., 2015). Later work reported that MOTS-c can regulate nuclear genes linked to metabolism and proteostasis, and examined age-related physical decline in mice.
The human side is observational. Exercise has been associated with increased endogenous MOTS-c in muscle and blood (Reynolds et al., 2021). That is a measurement of the body's own peptide, not a study of supplied MOTS-c. A 2023 review covers proposed links to diabetes and age-related disease while keeping that distinction (Kong et al., 2023).
Where the evidence stops: the mechanistic and outcome data are almost entirely cell and mouse work, and we found no completed controlled trial of MOTS-c itself. A related clinical programme tested an analog, not MOTS-c, so it should not be read as MOTS-c data. The MOTS-c listing is a laboratory reagent for that preclinical research context.
NAD+: a coenzyme, not a peptide
NAD+ (nicotinamide adenine dinucleotide) is an endogenous coenzyme. It carries electrons in the redox reactions of energy metabolism and is also consumed as a substrate by sirtuins, poly(ADP-ribose) polymerases (PARPs) and CD38, which ties it to DNA repair, chromatin regulation and immune-cell biology. Tissue NAD+ levels have been reported to decline with age in rodents and humans (Covarrubias et al., 2021).
Most human research on raising NAD+ has not used NAD+ itself. Many studies used oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). A crossover trial in healthy middle-aged and older adults reported that NR was tolerated and raised NAD+ levels (Martens et al., 2018), while a 2025 meta-analysis of NR and NMN trials in adults over 60 found no significant effect on muscle mass, strength or gait speed (Prokopidis et al., 2025). Animal evidence for NAD-boosting molecules is broader, and is reviewed in Rajman et al., 2018.
Where the evidence stops: precursor trials raise NAD+ metabolites but show mixed functional results, precursor data do not automatically transfer to NAD+ itself, and NAD+ is not an FDA-approved drug for any indication. NAD+ in our catalogue is a research compound.
Side by side: the evidence ladder
| Compound | Class and structure | Strongest evidence type | Status |
|---|---|---|---|
| SS-31 (elamipretide) | Synthetic tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2 | Registered clinical trials, small open-label extension | One drug product with FDA accelerated approval for one indication; other uses investigational |
| MOTS-c | 16-amino-acid mitochondria-encoded peptide | Cell and mouse studies; human observational data | Mostly preclinical |
| NAD+ | Endogenous coenzyme (not a peptide) | Small precursor trials (NR, NMN), meta-analysis | Investigational; not FDA-approved |
Read across the rows and the pattern is clear: the shared "mitochondrial" label tells you nothing about how far each line of research has travelled. A careful protocol cites the specific study model for each compound rather than borrowing evidence from its neighbours.
How a research lot is characterised
For any of these materials, the published literature only matters if the compound in the vial is the compound described. Each California Standard lot is released with a certificate of analysis that you can read before you pay. Two measurements carry most of the weight:
- HPLC (high-performance liquid chromatography) separates the main compound from related impurities. The certificate shows the chromatogram and states the measured purity for that specific lot.
- Mass spectrometry (MS) confirms identity by comparing the observed mass with the theoretical mass for the sequence. For SS-31 that includes the non-standard Dmt residue and the C-terminal amide, so a correct match is a meaningful check.
- Lot traceability: the lot number on the certificate should match the lot number on the vial.
If you want to see what a genuine certificate looks like, and the signs of one that is not, read how to spot a fake peptide COA.
Storage and specifications
| Product | House code | Container | Storage |
|---|---|---|---|
| SS-31 | CS-SS31 | Glass vial, crimp seal, flip-top cap | -20 °C, desiccated |
| MOTS-c | CS-MOTS | Glass vial, crimp seal, flip-top cap | -20 °C, desiccated |
| NAD+ | CS-NAD | Glass vial, crimp seal, flip-top cap | -20 °C, desiccated, protect from light |
Lyophilised material is best kept sealed, cold, dry and dark until it is used in the lab. Repeated warming and opening exposes the powder to moisture, which is the most common cause of degradation in storage.
Related reading: other short peptides with a much more concentrated, single-group literature are covered in bioregulator peptides: what the research shows.
Frequently asked questions
Is the SS-31 peptide the same as elamipretide?
Yes. SS-31, elamipretide and MTP-131 are names for the same tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2. The FDA accelerated approval applies to one manufactured drug product, elamipretide hydrochloride, for one Barth syndrome indication. It does not extend to research-grade SS-31.
Has the MOTS-c peptide been tested in controlled human trials?
We found no completed controlled trial of MOTS-c itself. Human data are largely observational, such as exercise-associated changes in the body's own MOTS-c levels. The mechanistic and outcome work is in cells and mice.
Is NAD+ a mitochondrial peptide?
No. NAD+ is a coenzyme, not a peptide. It is grouped with mitochondrial peptides because of its role in energy metabolism, and much of the human research used precursors such as NR and NMN rather than NAD+ itself.
What should a certificate of analysis for these compounds show?
A lot-specific HPLC chromatogram with the measured purity, a mass spectrum confirming identity against the theoretical mass, the testing laboratory, test dates and a lot number that matches the vial.
See it in the catalogue: SS-31 research peptide.
For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.